Ayala Pharmaceuticals Inc (ADXS)

[alexander77]

Aegis capital corp give ADXS $15/share target
1 other analyst firm gives almost the same target too

What is Aegis? Here is some background (pretty good!)

1. Head of Healthcare Equity Research

Raghuram “Ram” Selvaraju is Head of Healthcare Equity Research, Aegis Capital Corp., with 12 years of total experience in the biotech and pharmaceutical sectors. Dr. Selvaraju started his career in 2000 at the Serono Pharmaceutical Research Institute in Geneva, Switzerland, the applied research arm of Serono, Europe’s largest biopharmaceutical firm at the time. He began his research analyst career five years later in 2005 at Rodman & Renshaw; was senior vice president and Head of Healthcare Equity Research at Hapoalim Securities, the New York broker/dealer subsidiary of Israel’s largest financial services group, Bank Hapoalim, from 2009 to 2010; was a senior biotech analyst at Noble Financial Group in 2010-March 2011; most recently, he was senior vice president and senior biotechnology analyst for one year at Morgan Joseph TriArtisan LLC. He joined Aegis Capital Corp. as Managing Director and Head of Healthcare Equity Research in March 2012.

Dr. Selvaraju has been quoted in such publications as The Wall Street Journal, MSN Money, Barron’s, Bloomberg Businessweek, Reuters, Streetwise Reports, BioWorld Today, The Pink Sheet, PharmaVoice and BioCentury, and has also made multiple appearances on Bloomberg TV, Bloomberg Radio and CNBC, discussing biotech and pharmaceuticals stocks and the outlook for the healthcare industry. He has been ranked by StarMine based on earnings estimate accuracy and his team at Rodman & Renshaw was ranked #1 in The Wall Street Journal’s annual “Best On The Street” survey among biotechnology analysts based on overall portfolio return. He has published highly-regarded sector reports on Alzheimer’s disease, Multiple Sclerosis, stroke, orphan neurological disorders, and the most comprehensive Wall Street research produced to date on U.S. healthcare reform policy.

Among his academic qualifications, Dr. Selvaraju holds a Bachelor of Science in Biological Sciences and Technical Writing from Carnegie Mellon University, a Doctorate in Cell Biology and Neuroscience, a Master’s of Science in molecular biology from the University of Geneva in Switzerland, and an M.B.A. from Cornell University’s accelerated one-year program for scientists and engineers. Dr. Selvaraju has also published articles in leading peer-reviewed journals, presented research at various scientific conferences, and is a co-inventor on several drug development patents.


2. Associate Director – Healthcare and Technology Equity Research

Yi Chen, Ph.D. CFA, is an associate director in the equity research department of Aegis Capital Corp. Dr. Chen started his career on Wall Street in 2009 as a trading associate at Zhang Capital Management, a New York-based buy-side fund. Since early 2007, Dr. Chen was a research associate at the City University of New York in New York City, conducting research in the domains of protein signaling and RNA interference approaches. He obtained his Ph.D. in biochemistry from the City University of New York in February 2007. Dr. Chen started his career in equity research as a biotechnology equity research associate at Morgan Joseph TriArtisan LLC, a full-service investment bank based in New York City, in May 2011. He joined Aegis Capital Corp. as an associate director in the firm’s equity research group in March 2012. Dr. Chen possesses extensive domain expertise in the biotechnology and pharmaceuticals sectors, in addition to a substantial knowledge base in emerging markets geographies, particularly China. Fluent in oral and written Mandarin and English, he focuses on assessment of emerging opportunities in the China healthcare and technology sectors – among the fastest-growing in the world – in addition to researching investment opportunities in the U.S. healthcare sector. He has published articles in leading peer-reviewed journals, presented research at various scientific conferences, and has been an instructor in biology laboratory courses at Hunter College in New York City. He is also a Chartered Financial Analyst (CFA) charterholder.

http://www.aegiscapcorp.com/services/research/